Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Revenue growth of approximately 45% was driven by a dual increase in system sales and disposable probe utilization, signaling deeper integration into routine clinical practice.
Management identifies a new 'self-reinforcing cycle' where commercial adoption and real-world clinical evidence generation from the CHOICE study now directly fuel one another. The U.S. commercial footprint expanded by approximately 70% following FDA clearance for early-stage low-risk breast cancer, supported by targeted sales hires in key regions. Gross margin improvement to 30% was primarily attributed to increased scale and operating leverage, though gains were partially offset by unfavorable foreign exchange fluctuations.
Strategic positioning was bolstered by the inclusion of ProSense in the American Society of Breast Surgeons Resource Guide and ongoing efforts to include cryoablation in NCCN guidelines. International progress is centered on Japan, where the company is engaging with medical societies and partners to navigate the long-term regulatory and commercialization process. Management expects to achieve a near-term milestone with the enrollment of the first patients in the CHOICE study within the next 3 to 4 weeks.
The company remains on track to meet the FDA-mandated hurdle of 80 patients treated in the CHOICE study by March 2027. Financial planning assumes a traditional seasonal pattern where Q3 is typically lower due to global vacations, while Q4 is expected to be the strongest quarter of the year. The current cash position of approximately $12 million is intended to provide flexibility for continued commercial expansion, clinical evidence generation, and reimbursement initiatives.
Future growth is contingent on the successful transition of clinical investigators into active commercial users, a trend already observed in early CHOICE study participants. Foreign exchange fluctuations, specifically the U.S. Dollar versus the Israeli Shekel, significantly impacted the cost structure and moderated gross margin expansion.
R&D expenses increased to $4.3 million, primarily reflecting the costs associated with initiating the CHOICE post-market study and currency impacts on Israel-based operations. The company completed a financing round in the second quarter, raising approximately $8.5 million in gross profit to strengthen the balance sheet. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
